Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy and HAIC for Unresectable Cholangiocarcinoma
NCT06370663Phase 2Terminated
- Sponsor
- Shandong Cancer Hospital
- Start
- Apr 2024
- Primary completion
- Jun 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and oxaliplatin in cholangiocarcinoma (CCA) and gallbladder carcinoma, sponsored by Shandong Cancer Hospital. Primary endpoint: Adverse Events at 2 years. Started Apr 2024; status: terminated.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
cholangiocarcinoma (CCA)gallbladder carcinoma
Beyond the preview
Go deeper on NCT06370663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06370663.